Influenza virus infections are a major public health concern and cause significant morbidity
and mortality worldwide. Current influenza virus vaccines are an effective countermeasure …

Highlights•Broadly neutralizing antibodies against influenza A and B represents a safe and
affordable alternative to convalescent plasma.•The large majority of broadly neutralizing …

The generation of strain-specific neutralizing antibodies against influenza A virus is known
to confer potent protection against homologous infections. The majority of these antibodies …

The emergence of pandemic influenza viruses poses a major public health threat. Therefore,
there is a need for a vaccine that can induce broadly cross-reactive antibodies that protect …

IGHV polymorphism provides a rich source of humoral immune system diversity. One
important example is the IGHV1-69 germline gene where the biased use of alleles that …

Infection with influenza virus induces antibodies to the viral surface glycoproteins
hemagglutinin and neuraminidase, and these responses can be broadly protective. To …

Despite the availability of vaccine prophylaxis and antiviral therapeutics, the influenza virus
continues to have a significant, annual impact on the morbidity and mortality of human …

Influenza virus infections are a major public health concern and cause significant morbidity
and mortality worldwide. Current vaccines are effective but strain specific due to their focus …

Influenza remains a major global health burden. Seasonal vaccines offer protection but can
be rendered less effective when the virus undergoes extensive antigenic drift. Antibodies …

Current vaccines against influenza virus infection rely on the induction of neutralizing
antibodies targeting the globular head of the viral hemagglutinin (HA). Protection against …